Diebold Nixdorf (DBD)
NYSEInformation TechnologySoftware - ApplicationSnapshot 2026-09-09
$66.48-0.89%
Close 2026-09-09 · 1-day change
NYSEInformation TechnologySoftware - ApplicationSnapshot 2026-09-09
Intact: The reason to own it still holds.
Diebold Nixdorf grows revenue about 6% yearly and improves profit. Free cash flow is rising, with a target of $262.5 million in 2026. The company is stable with a price-to-earnings ratio of 15.45, well below peers. Management is focused on profitability and revenue growth, showing steady progress.
Revenue growth could slow below 3%, hurting profits. Rising costs might reduce operating income gains. Competition and technology shifts could pressure margins and cash flow.
The market prices in about 3% revenue growth and values the stock 42% below our fair value. We see upside from stronger growth and margin improvement than the market expects.
Breaks if: Free cash flow falls below $240M in FY26
Breaks if: Operating income falls below $30M in any quarter after 2026-Q1
Breaks if: Net income falls below $0 in any quarter after 2026-Q1
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a long-term thesis focused on a stable management team that is working to drive revenue growth and improve margins. The current state reflects a mix of recent earnings results, with some positive momentum but also risks from market conditions.
The market currently prices DBD as cheap compared to its peers, with a medium level of confidence in its valuation. There is an expectations gap, indicating that the market may not fully anticipate the potential for revenue growth and margin improvement.
Management is focused on expanding revenue and improving operating margins, with recent results showing positive trends in these areas. However, free cash flow has been mixed, which could impact future performance.
The thesis hinges on external factors such as potential interest rate cuts by the Fed and the performance of key sector peers like SAP and CRM. Additionally, any negative guidance from DBD could significantly impact market sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company reaffirmed its 2026 adjusted EBITDA target of $510M-$535M. This supports growth and capital objectives, which enhances the overall outlook. There are no new threats impacting the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on enhancing profitability and increasing net income.
Breaks if: Revenue falls below $3.8B in FY26
Overall, DBD is navigating a complex landscape with stable management and a focus on growth. The next few quarters will be crucial for assessing its long-term trajectory. Not investment advice.